Storia in 2 fonti

Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader

Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.

Raccontata da

endpoints.news

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo2 mesi fa

Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader

Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.

originale

biopharmadive.com2 mesi fa

Remix to go public in reverse merger with once high-flying Passage Bio

The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.

Leggi questa versione → originale

Timeline cronologica

mercoledì 24 giugno 2026·endpoints.news
Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader
Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.
giovedì 25 giugno 2026·biopharmadive.com
Remix to go public in reverse merger with once high-flying Passage Bio
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.